Compare PAI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAI | RCEL |
|---|---|---|
| Founded | 1973 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 102.5M |
| IPO Year | N/A | N/A |
| Metric | PAI | RCEL |
|---|---|---|
| Price | $12.39 | $3.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 25.0K | ★ 205.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,401,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $10.59 | $3.25 |
| 52 Week High | $12.63 | $14.16 |
| Indicator | PAI | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 43.10 |
| Support Level | $12.37 | $3.25 |
| Resistance Level | $12.50 | $3.58 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 44.89 | 44.00 |
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.